Siltuximab

Last Updated: 09/19/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 316 publications

Castleman disease: application of modern classification in a Canadian center.

Castleman disease: application of modern classification in a Canadian center.

Journal: Expert review of clinical immunology
Published: August 13, 2026

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies.

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies.

Journal: Expert opinion on biological therapy
Published: July 09, 2026

Interleukin-6 in hemolytic anemias: from inflammatory pathways to therapeutic targeting.

Interleukin-6 in hemolytic anemias: from inflammatory pathways to therapeutic targeting.

Journal: Frontiers in immunology
Published: June 25, 2026

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

Journal: Renal failure
Published: June 18, 2026

Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review.

Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 26, 2026

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal: Journal for immunotherapy of cancer
Published: May 21, 2026

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Published: May 15, 2026

Treatment of Castleman disease from the perspective of the year 2026.

Treatment of Castleman disease from the perspective of the year 2026.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: May 04, 2026

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Journal: BMJ case reports
Published: April 21, 2026

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

Journal: American journal of hematology
Published: April 18, 2026

Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies.

Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies.

Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

Journal: Cancers
Published: April 05, 2026
Showing 1-12 of 316

Last Updated: 09/19/2026